Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5550460 | 1.00 | FAAH (0.56) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL5550466 | 1.00 | FAAH (0.56) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL29235949 | 0.92 | FAAH (0.51) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL29114311 | 0.92 | FAAH (0.51) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL17003656 | 0.91 | FAAH (0.50) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL20787950 | 0.91 | FAAH (0.50) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL27057602 | 0.91 | HDAC3 (0.51) | FAAHGSK3AGSK3BPTGS1PTGS2 | |
| Lysine SCHEMBL6259867 | 0.88 | ITGB3 (0.50) | FAAHEPHX2 | |
| SCHEMBL31421913 | 0.87 | GSK3A (0.48) | FAAHGSK3AGSK3BEPHX2ACE | |
| SCHEMBL16847778 | 0.87 | ALDH1A1 (0.65) | FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | claimed |
| EP-4727586-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260034236-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | disclosed |
| EP-4570272-A1 | NEW DRUG COMPLEX | KOWA COMPANY, LTD. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| CN-119698305-A | New pharmaceutical complex | 兴和株式会社 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024258967-A1 | ANTI-CD5 ANTIBODIES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022191289-A1 | POLYION COMPLEX MICELLE ENCAPSULATING THEREIN CONTRAST AGENT CONTAINING PARAMAGNETIC, SUPER-PARAMAGNETIC OR FERROMAGNETIC TRANSITION METAL ELEMENT | 公益財団法人川崎市産業振興財団 | 2022-09-15 | — | — | WO | disclosed |
| CN-115052663-A | ALK5 inhibitor conjugates and uses thereof | 辛瑟斯治疗股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3520816-B1 | ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS | TAKEDA PHARMACEUTICALS CO (JP) | 2022-08-31 | — | — | EP | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3464294-B1 | ANTIBODY-DRUG-CONJUGATES COMPRISING NOVEL ANTHRACYCLINE-DERIVATIVES FOR CANCER TREATMENT | TOXINVENT OUE (EE) | 2022-07-13 | — | — | EP | disclosed |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2022-07-12 | — | — | US | disclosed |
| EP-3986468-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114269388-A | antibody-ALK 5 inhibitor conjugates and uses thereof | 辛瑟斯治疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473377-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | FAAH 1484/4885GSK3A 2505/4885GSK3B 2119/4885 |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | FAAH 1484/4885GSK3A 2505/4885GSK3B 2119/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | FAAH 1665/4885GSK3A 3468/4885GSK3B 3071/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | FAAH 1484/4885GSK3A 2505/4885GSK3B 2119/4885 |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | EGFR, ERBB2, ERBB3 | FAAH 3715/4885GSK3A 1034/4885GSK3B 1021/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | FAAH 3642/4885GSK3A 647/4885GSK3B 209/4885 |
| US-20260034236-A1 | NEW DRUG COMPLEX | OPRM1, ABCC1, OPRD1 | FAAH 966/4885GSK3A 4437/4885GSK3B 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.